BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 97 filers reported holding BRIDGEBIO PHARMA INC in Q1 2020. The put-call ratio across all filers is 0.20 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $123 | -62.0% | 4,656 | -76.2% | 0.00% | -75.0% |
| Q1 2023 | $324 | -99.8% | 19,545 | -8.3% | 0.00% | +33.3% |
| Q3 2022 | $212,000 | -80.9% | 21,316 | -82.6% | 0.00% | -75.0% |
| Q2 2022 | $1,111,000 | +263.1% | 122,311 | +305.9% | 0.01% | +500.0% |
| Q1 2022 | $306,000 | +29.1% | 30,134 | +112.3% | 0.00% | +100.0% |
| Q4 2021 | $237,000 | -80.1% | 14,195 | -44.0% | 0.00% | -83.3% |
| Q3 2021 | $1,188,000 | +4.3% | 25,337 | +35.6% | 0.01% | +20.0% |
| Q2 2021 | $1,139,000 | +27.5% | 18,680 | +28.9% | 0.01% | 0.0% |
| Q1 2021 | $893,000 | -32.2% | 14,495 | -21.8% | 0.01% | -28.6% |
| Q4 2020 | $1,318,000 | +131.6% | 18,532 | +22.3% | 0.01% | +75.0% |
| Q3 2020 | $569,000 | -13.7% | 15,158 | -25.0% | 0.00% | -20.0% |
| Q2 2020 | $659,000 | +53.6% | 20,198 | +36.5% | 0.01% | +25.0% |
| Q1 2020 | $429,000 | +123.4% | 14,792 | +170.0% | 0.00% | +100.0% |
| Q4 2019 | $192,000 | -59.7% | 5,478 | -69.0% | 0.00% | -33.3% |
| Q2 2019 | $476,000 | – | 17,647 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |